Dystrophin (DMD) Drugs In Development, 2021 Research Report – ResearchAndMarkets.com

Dystrophin (DMD) Drugs In Development, 2021 Research Report – ResearchAndMarkets.com




Dystrophin (DMD) Drugs In Development, 2021 Research Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dystrophin (DMD) – Drugs In Development, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Dystrophin (DMD) pipeline Target constitutes close to 57 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes.

Dystrophin (DMD) – Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It acts as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma.

The report ‘Dystrophin – Drugs In Development, 2021’ outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Dystrophin (DMD) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 6, 1, 31 and 9 respectively.

Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 5 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Musculoskeletal Disorders which include indications Duchenne Muscular Dystrophy, Alport Syndrome and Muscular Dystrophy.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Dystrophin (DMD)
  • The report reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Dystrophin (DMD) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Dystrophin (DMD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Dystrophin (DMD) targeted therapeutics

Key Topics Covered:

  • Introduction
  • Overview
  • Therapeutics Development
  • Therapeutics Assessment
  • Companies Involved in Therapeutics Development
  • Drug Profiles
  • Dormant Products
  • Discontinued Products
  • Product Development Milestones
  • Appendix

Companies Mentioned

  • Alpha Anomeric
  • Astellas Gene Therapies
  • Code Biotherapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Dystrogen Therapeutics SA
  • Editas Medicine Inc
  • Evox Therapeutics Ltd
  • FibroGenesis LLC
  • MyoGene Bio LLC
  • Myosana Therapeutics Inc
  • Vertex Pharmaceuticals Inc
  • Wave Life Sciences Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tvj5ee

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900